Entering text into the input field will update the search result below

The FDA rejects Amgen's (NASDAQ:AMGN) application to expand the use of the drug Xgeva to delay...

Apr. 27, 2012 4:04 AM ETAmgen Inc. (AMGN) StockAMGNBy: Rachael Granby, SA News Editor
The FDA rejects Amgen's (NASDAQ:AMGN) application to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer. It's a blow for Amgen, as analysts see Xgeva and a related osteoporosis drug Prolia as among the most important growth drivers for the company.

Recommended For You

More Trending News

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.